Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total value of $153,397.71.
- On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00.
- On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00.
Halozyme Therapeutics Trading Up 2.6%
Shares of HALO traded up $2.73 during trading hours on Wednesday, hitting $107.62. The stock had a trading volume of 2,539,028 shares, compared to its average volume of 2,401,815. The company’s fifty day simple moving average is $81.71 and its 200 day simple moving average is $73.26. The firm has a market cap of $12.21 billion, a P/E ratio of 32.13, a P/E/G ratio of 0.42 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $107.96.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on HALO shares. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.
Hedge Funds Weigh In On Halozyme Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of HALO. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $27,000. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth about $28,000. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $30,000. Institutional investors own 97.79% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
- Five stocks we like better than Halozyme Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
